RheumaView Insights · Nephropathology

Lupus Nephritis by Class: What the Biopsy Tells You

Six patterns of kidney injury in lupus — and why the exact spot a deposit lands decides the outcome.

Under the microscope, lupus nephritis resolves into six patterns, and the classification turns on one variable: where in the glomerulus the immune complexes came to rest. Complexes formed in lupus lodge in the kidney, fix complement, and provoke injury. Deposits held in the mesangium may leave filtration untouched, while the same complexes along the subendothelial wall set off a florid nephritis, and on the outer, subepithelial face they drive heavy protein loss with little inflammation to show for it. The serology can read the same across all of it; the biopsy is what tells them apart.

That is why the ISN/RPS system classifies by site. It maps where the deposits sit instead of cataloguing the patient’s symptoms, and the six resulting classes behave differently enough that each demands its own management.

Lupus nephritis is not a rare complication. It develops in roughly a third to more than half of people with systemic lupus, and it stays among the strongest predictors of long-term kidney loss and early death in the disease. The distinction is not academic: a mesangial pattern and a diffuse proliferative one send the same kidney down very different paths.

The mesangial classes: mostly quiet

Deposits confined to the mesangium make little noise. Class I is invisible on light microscopy; the immune deposits show up only on immunofluorescence and electron microscopy. Class II adds mesangial hypercellularity and matrix expansion, and it usually presents as microscopic hematuria with modest proteinuria. The capillary loops stay open, filtration is preserved, and these are the biopsies a nephrologist is often content to monitor rather than treat aggressively.

Into the capillary wall: the proliferative classes

The moment deposits reach the subendothelial space, the disease turns inflammatory. Class III is focal, with active lesions in fewer than half the glomeruli. Class IV is diffuse, involving fifty percent or more, and it is the most common and the most dangerous pattern. Under the scope you see endocapillary proliferation — cells packing the capillary lumen — and the wire-loop lesions that betray heavy subendothelial deposition. Clinically it reads as an active nephritis: hematuria, rising proteinuria, hypertension, and a GFR that slips. Left alone, Class IV walks a patient toward dialysis.

One immunofluorescence finding comes close to a signature. Lupus nephritis tends to light up for the whole panel of immunoreactants at once — IgG, IgA, IgM, C3, and C1q, the so-called full-house pattern — which is unusual in other glomerular diseases and helps anchor the diagnosis when the clinical picture is muddy.

The outer surface, and the end of the line

Cross to the subepithelial side and lupus nephritis changes character again. Class V — membranous — thickens the capillary wall with deposits sitting on the podocyte side of the membrane, so the dominant problem is nephrotic-range protein loss with comparatively little inflammation. It can also ride alongside Class III or IV, and those mixed lesions carry the liabilities of both. Class VI is the burnt-out kidney: ninety percent or more of glomeruli globally sclerosed, without residual activity. By that stage immunosuppression has nothing left to act on, and the task shifts to managing advanced disease and planning renal replacement.

Two kidneys can share the label Class IV and still call for opposite treatment.

Activity versus chronicity

One reading matters as much as the class itself. The pathologist scores activity — the inflammatory changes that treatment can reverse — apart from chronicity, the scarring it cannot. Two biopsies both labeled Class IV can demand opposite decisions: aggressive induction for the one that is inflamed and salvageable, supportive care for the one that has already sclerosed. A class number tells you the pattern; the activity and chronicity indices tell you whether there is anything left to save.

The classification is not fixed in a given patient, either. A kidney can transform from one class to another as the disease evolves — a quiet mesangial pattern flaring into diffuse proliferative injury, or a treated proliferative lesion settling into membranous disease. Transformation can run in either direction, and it does not always announce itself in the urine. That is why a repeat biopsy earns its place when the clinical course and the last histology stop agreeing.

Treatment has quietly changed

For decades the toolkit was blunt. Corticosteroids to quench inflammation fast; mycophenolate or cyclophosphamide to halt dividing immune cells; a calcineurin inhibitor such as tacrolimus to steady the podocyte and cut protein loss; rituximab used off-label when B cells needed removing. The last five years added precision to that backbone. Belimumab, which blocks the B-cell survival factor BAFF, and voclosporin, a next-generation calcineurin inhibitor, both earned dedicated lupus-nephritis indications. In October 2025 the FDA approved obinutuzumab, a type II anti-CD20 antibody that strips out B cells more completely than rituximab, on the strength of the phase III REGENCY trial — where 46% of patients reached a complete renal response against 33% on standard therapy alone. Induction now leans on combinations — a mycophenolate-and-steroid backbone paired with a targeted agent — with the aim of reaching a complete renal response sooner and tapering steroids faster.

The frontier

Further out sits the experimental edge, and it is unusually lively. CAR-T therapy re-engineers a patient’s own T cells to wipe out and reset the B-cell compartment; early case series in refractory lupus have produced drug-free remissions that older biologics never reached. Anifrolumab, already approved for systemic lupus, blocks type-I interferon and is in phase III trials for the kidney. Anti-CD38 antibodies aimed at the plasma cells that outlive anti-CD20 therapy, BTK inhibitors, and complement blockers are moving through earlier-stage studies.

Which drug to reach for, though, still follows from the lesion on the slide. The class points to the mechanism, and a growing shelf of agents is built to hit one mechanism at a time — so the same biopsy that named the disease increasingly helps choose what treats it.